This protocol will confirm toxicities and estimate the clinical efficacy of combining
anti-CD3 x anti-EGFR bispecific antibody (EGFRBi) armed activated T cells (EGFR BATs) given
to patients with locally advanced or metastatic pancreatic cancer who have received at least
one dose of first line chemotherapy and may have responding, stable or progressive disease.
Phase Ib will confirm a safe dose of 8 infusions, given twice weekly, of EGFR-BATs in 3 to 6
subjects. The phase II portion of the trial will test the clinical efficacy of this dose in
22 patients (including those in Phase Ib).